This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of cookies and the other terms of our Privacy Policy. For more information, please visit our Privacy Policy.

ABOUT REVCOVI (elapegademase-lvlr)

Revcovi is an enzyme replacement therapy (ERT) indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.1

Revcovi is the product of recombinant technology. It is a PEGylated recombinant adenosine deaminase (rADA) enzyme.1

DOSING AND ADMINISTRATION

Dose titration along with careful lab monitoring helps customize Revcovi treatment to each patient’s individual needs.1

REVCOVI ORDERING & SUPPORT

Chiesi offers patient support services through Chiesi Total Care to aid patients, caregivers, and healthcare providers with coverage and reimbursement concerns.

REVCOVI HEALTHCARE
PROFESSIONALS BROCHURE

Download a brochure about Revcovi, including efficacy and safety data, dosing and monitoring information, how to order, patient support programs, and information about diagnosing ADA-SCID.

DOWNLOAD

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
  • Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

ADVERSE REACTIONS

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:

  • Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
  • Dermatological events: injection site erythema, urticaria
  • Lymphomas

IMPORTANT MONITORING INFORMATION

Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

INDICATION

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

Please see the Full Prescribing Information.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
  • Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

ADVERSE REACTIONS

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:

  • Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
  • Dermatological events: injection site erythema, urticaria
  • Lymphomas

IMPORTANT MONITORING INFORMATION

Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

INDICATION

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

Please see the Full Prescribing Information.

Reference
  1. Revcovi. Prescribing information. Chiesi USA, Inc.; 2021.
You are now leaving the Revcovi HCP website.

This external link is provided for your convenience. Chiesi is not responsible for content on external websites.

Ok, ContinueReturn to Site